Combined-modality therapy for esophageal and gastroesophageal junction cancers.
The optimal management of locoregional esophageal cancer is controversial. Preoperative concomitant chemoradiotherapy (two courses of cisplatin and 5-fluorouracil plus 50 Gy of radiation) may provide benefit in survival and local control compared with surgery alone and is a reasonable alternative to surgery alone in stages IIB, III, and possibly stage IVa disease. This benefit is less clear in stages I and IIA, for which surgery alone is thus a reasonable option. Preoperative chemotherapy without radiation also provides a survival benefit compared with surgery alone, but data are insufficient to conclude it is superior to preoperative chemoradiotherapy. Control of distant disease remains a problem with preoperative chemotherapy and preoperative chemoradiotherapy.
Yoon
Harry H
HH
Upper Aerodigestive Group, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building II 553, Baltimore, MD 21231, USA.
Gibson
Michael K
MK
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000473:pathology / Q000628:therapy*; D016629:Esophagectomy; D004943:Esophagogastric Junction / Q000473:pathology*; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D020360:Neoadjuvant Therapy; D009362:Neoplasm Metastasis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic
D002945:Cisplatin; D005472:Fluorouracil